LIfT BioSciences to present preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils at the 40th Society for Immunotherapy of Cancer

London, 5 November 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces that preclinical data demonstrating the potential of its first-in-class Immunomodulatory Alpha Neutrophils (IMANs) to restore innate immune competence and remodel the tumour microenvironment (TME) in support of anti-tumor immunity, will be presented in a poster at the 40th Society for Immunotherapy of Cancer being held from 5-9 November in National Harbor, Maryland.

Key data highlights

• IMANs exhibited physiological biodistribution, safety and consistent tumor infiltration in vivo, resulting in recruitment of T and NK cells
• In preclinical tumor models, IMANs enhanced effector cell recruitment, resulting in increased tumor cell death. Additionally, they synergised with CAR-T cells to enhance tumor clearance in models of treatment-resistant cervical and pancreatic cancers
• Overall, IMANs exhibited robust, antigen-independent cytotoxicity across multiple tumor types, demonstrating potential to target antigen escape variants that drive metastatic progression in cancer
  
  

Poster information
Title: IMANs: A transformative allogeneic neutrophil cell therapy for rejuvenating innate immunity and overcoming treatment resistance in solid tumours
Presenter:   Aoife M McGinley
Date and time: 7 November 2025, 17:35-19:00 ET
Abstract number: 645

Alex Blyth, Chief Executive Officer of LIfT BioSciences, commented: “Being selected to present our latest data underscores growing recognition of our IMAN platform’s potential to transform immuno-oncology. Our findings highlight how our first-in-class IMANs can restore innate immune competence and drive adaptive immune activation in solid tumors. With scalable, off-the-shelf manufacturing and a lower cost profile than many current cell therapies, IMANs have the potential to deliver broad clinical impact across oncology and immune-mediated diseases.”

About LIfT BioSciences
LIfT BioSciences is a UK and Ireland-based biotech pioneering a first-in-class allogeneic alpha neutrophil immunotherapy that overcomes treatment resistance in solid tumours by restoring immune competence. Its Immuno-Modulatory Alpha Neutrophils (IMANs) recognise and destroy cancer cells through advanced threat pattern recognition in a non-antigen-specific manner. Clinical studies show that this class of neutrophils can prevent tumour escape—responsible for over 90% of cancer-related deaths—by delivering a durable, total immune response and lasting immunity.

LIfT’s patented N-LIfT platform is derived from exceptional donor stem cells cultured in a proprietary enhancement media, enabling scalable and potent cell production. The company is also advancing iPSC technology and genetic engineering to create next-generation IMAN therapies with pharma partners to achieve cost-effective, long-term remission for cancer patients and beyond. LIfT is currently completing its 2nd close on its Series A round. See www.LIfTBiosciences.com

Further information
Investors:
Alex Blyth
ablyth@LIfTBioSciences.com

Media:
ICR Healthcare
Lindsey Neville, Namrata Taak, Evi Useh
liftbiosciences@icrhealthcare.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.